pharma

Gland Pharma

GLAND · Nifty 50

2,197.6

Price 2026-06-17

BROAD EXPANSION73% confidence

At a Glance

Sector Positionpharma sector. Flow: neutral. is not among current leaders. Regime: BROAD EXPANSION (73%).
Fundamental Score75/100 (STRONG). 1 positive flags, 1 concerns.
Historical Context54 similar technical setups. Average outcome: -7.9% decline. 0% positive.

Fundamental

75/100

STRONG

Trust

95/100

Verification

Coverage

44/100

LIMITED

Quick Take

Gland Pharma scores 75/100 on fundamentals (strong). Gland Pharma: BROAD EXPANSION regime.

Fundamental Score: 75/100 · STRONG · 0 signals detected

DuPont Analysis

ROE 9.9% broken into three drivers. Each shows how efficiently the company generates returns.

ROE9.9%=
16.2%Net Margin
×
0.5xTurnover
×
1.2xLeverage

ROE of 9.95% is modest margin-driven and stable. Net margin of 16.2% × asset turnover of 0.51x × leverage of 1.2x.

What This Means

Net margin of 16.2% means the company keeps ₹16.2 as profit for every ₹100 of revenue. This is a healthy margin. Asset turnover of 0.51x means the company efficiently uses its assets to generate revenue. Leverage of 1.2x means the company uses moderate debt. Returns are primarily driven by operations, not borrowing.

Margin Structure

Gross

65.8%

Operating

23.6%

Net

16.2%

improving

Gross margin 65.8% → operating margin 23.6% → net margin 16.2%. Margins are IMPROVING. Strong pricing power with stable gross margins suggests the improvement is from operating leverage — sustainable.

Financial Health

Earnings Quality

ADEQUATE

Cash flow only covers 1.0x of net income — earnings quality is WEAK. Profit may not be converting to cash. Check receivables and inventory.

Debt Sustainability

COMFORTABLE

Interest covered 45.6x — very comfortable. Debt service is not a concern. Debt/EBITDA at 0.1x is low — balance sheet has capacity.

Free Cash Flow

STRONG

FCF margin at 8.4% — moderate. Generating cash after investments.

Peer Comparison

Gland Pharma is compared against 10 peers in the pharma sector.

Key Watchpoints

🟢

Breaks above ₹2307 (+5%)

Trend reversal confirmation

🔴

Breaks below ₹2088 (-5%)

Further downside risk

🟢

Pharma sector entering leadership

Sector rotation signal

Risk Flags

⚠️ 1 Warning1 Positive2 total flags
⚠️61% of debt is short-term
Balance Sheet

High refinancing risk. Company needs to roll over debt frequently. Vulnerable to credit market freezes.

Minimal unusual items — clean earnings
Earnings Quality

Profits are from core operations, not one-offs. High quality.

➡️ 2 flags — 1 positive, 1 warning. Mixed profile.

Data Quality

95/100All ratios self-computed from verified sources. 🟢 5 years of financial data — sufficient for trend analysis

News Correlation

margin pressure (4)management outlook (4)
⚠️ Our margin analysis (improving) contradicts news reports of margin pressure — investigate

50 articles scanned for fundamental themes

Facts

P/E Ratio
36.3UNAVAILABLE
P/B Ratio
3.6HIGH
Market Cap
₹3731717.8L CrHIGH
From 52W High
92% of high
Sector Peers
10
Gland Pharma Stock Analysis, Valuation, Fundamentals & Intelligence | FynSight